

Laparoscopic versus open nephroureterectomy for upper urinary tract urothelial carcinoma

A systematic review and meta-analysis

Feng Liu, MS^a, Wei Guo, BS^b, Xueying Zhou, BS^c, Youpeng Ding, MS^d, Yanan Ma, MS^d, Yi Hou, MS^d, Xiangbo Kong, BS^d, Zhixin Wang, MD^{d,*}

Abstract

Purpose: To evaluate the efficacy and safety of laparoscopic nephroureterectomy (LNU) and open nephroureterectomy (ONU) for the treatment of upper urinary tract urothelial carcinoma (UTUC).

Methods: PubMed, Embase, and Cochrane databases were selected for systematic review of trials that compared outcomes of LNU and ONU. Meta-analysis was performed using RevMan 5.3 and STATA 13.0 software.

Results: LNU was associated with longer operation time (P < .001), shorter hospital stay (P < .001), less blood loss (P = .006) and lower rate of transfusion (P < .001). The occurrence of complications, including minor (P = .52), major (P = .21) and total complications (P = .19) were similar between LNU and ONU. There was no significant difference in the rate of 5-year recurrence-free survival (P = .90), 5-year cancer-specific survival (P = .12), and 5-year overall survival (P = .11) as well as 2-year RFS (P = .84), 2-year CSS (P = .86), and 2-year OS (P = .25).

Conclusion: Our results indicated that LNU is a safe and effective method to treat UTUC. Given the limitations of this study, further multicenter, randomized trials are required to confirm these findings.

Abbreviations: CIs = confidence intervals, CSS = cancer-specific survival, FE = fixed-effects, LNU = laparoscopic nephroureterectomy, ONU = open nephroureterectomy, OR = odds ratio, OS = overall survival, RE = random-effects, RFS = recurrence-free survival, RR = risk ratio, UTUC = urinary tract urothelial carcinoma, WMD = weighted mean difference.

Keywords: laparoscopic nephroureterectomy, meta-analysis, open nephroureterectomy, urinary tract urothelial carcinoma

1. Introduction

Urothelial carcinoma of the upper urinary tract (UTUC) is a type of rare malignancy accounting for 1% to 5% of all urological tumors.^[1] Due to its characteristics of rapid progression, tissue invasion and body deterioration, radical nephroureterectomy with bladder cuff excision is the standard treatment for UTUC, especially for muscle-invasive and/or high-grade disease.^[2]

Currently, open nephroureterectomy (ONU) is the most commonly performed procedure for high-risk UTUC. Although

This study was supported by Jilin Science and Technology Department (Bethune Special Project) (No.3D516M403430). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

The authors have no conflicts of interest to disclose.

^a Department of Nephrology, ^b Department of Out Patient, ^c Department of Operation Room, ^d Department of Urology, China–Japan Union Hospital of Jilin University, Changchun, PR China.

^{*} Correspondence: Zhixin Wang, Department of Urology, China–Japan Union Hospital of Jilin University, Changchun 130033, PR China (e-mail: wzx603923@aliyun.com).

Medicine (2018) 97:35(e11954)

Received: 1 February 2018 / Accepted: 27 July 2018 http://dx.doi.org/10.1097/MD.000000000011954 ONU has been proven to provide long-term local control and improve survival, it may be associated with significant morbidity.^[2] Since the first laparoscopic nephroureterectomy (LNU) was performed in 1991, minimally invasive approaches have rapidly evolved, and laparoscopic surgery of the upper urinary tract has become increasingly accepted by the urological community.^[3] LNU is considered to be equally effective as ONU surgery for UTUC, while resulting in less perioperative morbidity. However, UTUC is biologically aggressive malignancy with a high potential for disease recurrence and eventual death. It is hypothesized that tumor dissection and high-pressure pneumoperitoneum during LNU are associated with a higher risk of bladder or local recurrence as well as port-site metastasis.^[4] Hence, the oncologic efficacy of LNU versus ONU remains controversial.

Several studies have compared the outcomes of LNU and ONU for selected cases of UTUC. Nevertheless, the role of LNU is not yet established. Although a meta-analysis comparing LNU and ONU was published in 2012,^[5] the surgical technique and experience have vastly developed since then. Hence, we conducted this meta-analysis based on trials published in the past 10 years, to evaluate the advantages and disadvantages of LNU for the surgical treatment of UTUC in terms of perioperative, postoperative and survival parameters.

2. Materials and methods

The present meta-analysis was conducted based on the recommendations of the PRISMA guidelines. All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

Editor: Giuseppe Lucarelli.

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

2.1. Study selection

A systematic search of PubMed, Embase, and Cochrane online databases was performed to identify all studies published in the past 10 years (2007–2017), which compared LNU with ONU using the following MESH search headings: "comparative studies," "laparoscopic," "open," "radical nephroureterectomy," and "urothelial carcinoma of the upper urinary tract." The "related articles" function was used to broaden the search, and all abstracts, studies, and citations were reviewed. Additionally, the reference lists of selected articles were manually reviewed to identify other potentially relevant articles.

2.2. Inclusion and exclusion criteria

The included trials met the following requirements: studies comparing LNU with ONU, patients with urothelial carcinoma of the upper urinary tract, reports on at least one outcome of interest mentioned below such as operation time, hospital stay, estimated blood loss, blood transfusion, complications, 5-year and/or 2-year survival and the relative data were reported or could be calculated, and published in the last 10 years (2007–2017).

Studies were excluded if the inclusion criteria were not met, no outcomes of interest were reported or it was impossible to calculate or extrapolate the necessary data from the published results, children were included in the studies, and published before 2006.

2.3. Data extraction and outcomes of interest

Two reviewers independently extracted the following data: first author, year of publication, country, study interval, study design, number of patients who underwent LNU or ONU, mean age of the patients, ratio of males and females and length of follow-ups. The study qualities were assessed using the Newcastle–Ottawa scale (NOS).^[6] Pathological stage and grade of tumor were also collected.

The following outcomes were extracted to compare LNU and ONU. Perioperative variables including operation time, length of hospital stay, and blood transfusion rate. Postoperative complications including minor complications (Clavien grades 1 and 2), and major complications (Clavien grades 3–5). The oncological outcomes including 2-year and 5-year recurrence-free survival (RFS), 2-year and 5-year cancer-specific survival (CSS), and 2-year and 5-year overall survival (OS).

In all cases of missing or incomplete data, the corresponding authors were contacted, but no additional information was provided. If no response was received, the methods introduced by Tierney were used to calculate or estimate the useful data from other information, such as the Kaplan–Meier curves.^[7] All disagreements about eligibility were resolved by a third author through discussion until a consensus was reached.

2.4. Statistical analysis

The weighted mean difference (WMD) was used for continuous variables, the odds ratio (OR) was used for dichotomous parameters and the risk ratio (RR) for survival parameters, all with 95% confidence intervals (CIs). For studies presenting continuous data as means and range, we made an approximate transformation using the technique described by Hozo et al.^[8] All pooled effects were determined by the *z* test and P < .05 was considered statistically significant. The heterogeneity of the treatment effects among included trials was evaluated using Q

statistic and I^2 statistic. When $I^2 < 50\%$, P > .1, the evidences showed no significant heterogeneity, we used fixed-effects (FE) model, otherwise we used random-effects (RE) model. Sensitivity analyses were performed by omitting one study at a time. All the statistical analyses were performed using RevMan 5.3 (Cochrane Library Software, Oxford, UK). Egger's test and Begg's test were used to assess publication bias. All reported *P* values were 2-sided and P < .05 was regarded as significant for all included trials. The trim-and-fill method was also used to overcome the publication bias.^[9] This process was done by STATA (Version 13.0; Stata Corp, Texas).

3. Results

3.1. Characteristics of selected studies

A total of 394 records were retrieved through database search. After screening, 25 trials^[10–35] were selected for our metaanalysis (Fig. 1), which included 3489 patients who underwent LNU and 5732 patients who underwent ONU. The NOS of included studies ranged from 5 to 8. The characteristics of these studies are shown in Table 1. The pathological stages and grades



Figure 1. Flowchart showing the study selection process for meta-analysis.

Zou, 2014

Table 1 Characteristics of the included studies.

First author, year	Country	Study interval	Study type	Age mean (range)	Gender, Male/Female	No. of patients, LNU/ONU	Follow-up/months mean (range)	NOS
Ariane 2012	France	1995–2010	Retrospective	69.8 (61.9–76)	415/194	150/459	27 (10–48)	6
Blackmur, 2015	UK	1992-2010	Retrospective	67.8 (57.1–77.3)	14/12	13/13	2.8–187	6
Capitanio, 2009	Multi Institutional	1987-2007	Retrospective	68.7 (27–97)	846/403	270/979	60	8
Fairey, 2013	Multi Institutional	1994–2009	Retrospective	71.5	542/307	446/403	26.4 (7.2-60)	7
Favaretto, 2010	USA	2002-2008	Retrospective	71.7 (64–78)	NA	53/109	60	6
Fradet, 2014	Canada	1990-2010	Retrospective	67 (59–75)	NA	345/267	40.4 (7.7-56.8)	7
Greco, 2009	Germany	1999–2003	Retrospective	66.8	76/64	70/70	60	7
Hanske, 2015	Multi Institutional	2006-2012	Retrospective	70.3	573/323	599/297	1	6
Hemal, 2008	India	1998-2006	Retrospective	55.9	27/21	21/27	55.3 (3-79)	6
Kim, 2015	Korea	1992-2012	Retrospective	64.7 (57.7-70.8)	287/84	100/271	50.8 (26.6-103.6)	8
Kitamura, 2014	Japan	1995-2010	Retrospective	68.3 (32-88)	NA	65/34	60 (6-192)	6
Koda, 2007	Japan	1995-2005	Retrospective	70.4	80/26	79/27	17.5 (1-97)	8
Liu, 2017	China	2000-2013	Retrospective	62	198/67	52/213	60	8
Manabe, 2007	Japan	2000-2004	Retrospective	72 (48-84)	154/70	58/166	13.6–28	6
Metcalfe, 2012	Canada	1994–2009	Retrospective	69.7	653/375	446/403	60	5
Miyazaki, 2016	Japan	2005-2011	Retrospective	69.7	504/245	222/527	39 (0.1-79.3)	6
Rouprêt, 2007	France	1994–2004	Retrospective	70	34/12	20/26	24	7
Simone, 2009	Italy	2003-2006	RCT	60.45	50/30	40/40	41 (30-66)	8
Stewart, 2011	UK	1992-2000	Retrospective	67.8	33/29	23/39	163	7
Taweemonkongsap, 2008	Thailand	2001-2007	Retrospective	65.25	33/27	31/29	27.1 (3-72)	7
Terakawa, 2008	Japan	2000-2005	Retrospective	70	NA	120/120	29.5	7
Waldert, 2008	Austria	1999–2006	Retrospective	67.2	61/31	43/59	41	7
Walton, 2010	Multi Institutional	1987–2008	Retrospective	68 (61-75)	533/240	70/703	34 (15-65)	7
Xylinas, 2013	France	1995-2009	Retrospective	67.7 (60-76)	332/150	132/350	39.5 (25-60)	5

63.7 (35-80)

LNU=laparoscopic nephroureterectomy, NA=not applicable, NOS=Newcastle-Ottawa Scale, ONU=open nephroureterectomy, RCT=randomized controlled trial.

Retrospective

1999-2013

(if available) of involved patients from the trials are shown in Tables 2 and 3.

3.2. Outcomes of perioperative variables

China

The LNU group was associated with longer operation time/min (WMD: 44.85; 95% CI: 24.89 to 64.80; P < .001). The hospital stay was significantly shorter in the LNU group (WMD: -2.46;

Table 2									
Pathological stages of the patients in the included trials.									
First author,	Ta, Tis	T1	T2	T3	T4				
year	(LNU/ONU)	(LNU/ONU)	(LNU/ONU)	(LNU/ONU)	(LNU/ONU)				
Ariane, 2012	44/119	31/113	20/45	53/153	2/29				
Blackmur, 2015	10/10	0/0	1/1	2/2	0/0				
Capitanio, 2009	103/204	69/229	35/202	59/306	4/38				
Fairey, 2013	NA	NA	66/66	99/89	21/22				
Greco, 2009	13/14	17/16	39/37	1/3	0/0				
Hemal, 2008	3/4	8/9	8/11	2/3	0/0				
Kitamura, 2014	3/16	7/10	8/11	16/28	0/0				
Koda, 2007	17/8	20/6	11/6	28/7	3/0				
Liu, 2017	0/0	20/65	10/46	NA	NA				
Manabe, 2007	12/29	16/41	6/16	24/73	0/7				
Miyazaki, 2016	0/0	0/0	58/154	154/329	10/44				
Rouprêt, 2007	6/6	9/5	2/5	2/7	1/3				
Simone, 2009	0/0	20/12	8/15	12/13	0/0				
Stewart, 2011	10/20	7/8	3/2	3/9	0/0				
Taweemonkongsap,	0/0	16/13	10/12	4/4	1/0				
2008									
Terakawa, 2008	34/24	25/26	19/27	40/43	2/0				
Waldert, 2008	11/13	9/16	5/10	18/20	0/0				
Walton, 2010	10/153	20/175	8/139	19/196	4/40				
Zou, 2014	0/0	8/40	10/38	2/18	1/5				

LNU = laparoscopic nephroureterectomy, NA = not applicable, ONU = open nephroureterectomy.

95% CI: -3.12 to -1.80; P < .001) as compared to the ONU group. Besides, LNU resulted in less estimated blood loss (WMD: -137.83; 95% CI: -236.77 to -38.89; P=.006) and consequently lower rate of blood transfusion (OR: 0.43; 95% CI: 0.31 to 0.60; P < .001). These perioperative outcomes are shown in Figure 2.

21/101

53 (3-159)

6

3.3. Outcomes of complications

87/35

We pooled data on complications from the included studies. The results showed no significant differences between LNU and ONU in minor (OR: 1.17; 95% CI: 0.73 to 1.88; P=.52), major (OR: 0.63; 95% CI: 0.31 to 1.29; P=.21) and total complications (OR:

Table 3								
Pathological grades of the patients in the included trials.								
First author, year	G1 (LNU/ONU)	G2 (LNU/ONU)	G3 (LNU/ONU)					
Ariane, 2012	11/39	41/166	98/254					
Blackmur, 2015	1/1	9/9	3/3					
Greco, 2009	15/17	47/45	8/8					
Hemal, 2008	6/8	11/13	4/6					
Kitamura, 2014	1/2	14/33	19/30					
Koda, 2007	10/3	33/16	36/8					
Manabe, 2007	4/15	31/87	23/64					
Miyazaki, 2016	4/8	72/189	146/324					
Simone, 2009	6/5	22/22	12/13					
Stewart, 2011	3/4	7/20	13/15					
Terakawa, 2008	8/15	69/57	43/48					
Waldert, 2008	6/4	19/31	18/24					
Walton, 2010	11/88	5/219	54/396					

LNU = laparoscopic nephroureterectomy, ONU = open nephroureterectomy.



1.22; 95% CI: 0.91 to 1.65; P=.19). The data are shown in Figure 3.

3.4. Outcomes of survival

Survival variables were compared between LNU and ONU. The rate of 5-year RFS (RR: 1.01; 95% CI: 0.92 to 1.10; P=.90),

5-year CSS (RR: 1.04; 95% CI: 0.99 to 1.10; P=.12), and 5-year OS (RR: 1.08; 95% CI: 0.98 to 1.18; P=.11) as well as 2-year RFS (RR: 0.99; 95% CI: 0.87 to 1.12; P=.84), 2-year CSS (RR: 1.01; 95% CI: 0.94 to 1.07; P=.86) and 2-year OS (RR: 1.04; 95% CI: 0.97 to 1.12; P=.25) were similar between the LNU group and ONU group. The survival comparisons are shown in Figure 4.

Minor complication	ons LNU		ONU	J		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ariane 2012	12	150	42	459	61.3%	0.86 [0.44, 1.69]	
Blackmur 2015	3	13	2	13	5.0%	1.65 [0.23, 11.99]	
Hemal 2008	3	21	3	27	7.2%	1.33 [0.24, 7.39]	
Stewart 2011	7	23	5	39	8.3%	2.98 [0.82, 10.83]	
Terakawa 2008	7	120	6	120	18.2%	1.18 [0.38, 3.61]	
Total (95% CI)		327		658	100.0%	1.17 [0.73, 1.88]	+
Total events	32		58				
Heterogeneity: Chi ² =	2.93, df =	4 (P =	0.57); 12=	= 0%			
Test for overall effect:	Z = 0.65 ((P = 0.5	52)				0.01 0.1 1 10 100 Favours [LNU] Favours [ONU]
Major complication	ons lnu	1	ONU	J		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ariane 2012	7	150	19	459	42.9%	1.13 [0.47, 2.75]	
Blackmur 2015	0	13	2	13	11.6%	0.17 [0.01, 3.92]	
Hemal 2008	0	21	2	27	10.3%	0.24 [0.01, 5.21]	
Rouprêt 2007	0	20	1	26	6.2%	0.41 [0.02, 10.73]	
Stewart 2011	1	23	5	39	17.1%	0.31 [0.03, 2.83]	
Terakawa 2008	0	120	2	120	12.0%	0.20 [0.01, 4.14]	
Total (95% CI)		347		684	100.0%	0.63 [0.31, 1.29]	•
Total events	8		31				
Heterogeneity: Chi ² =	3.75, df =	5 (P =	0.59); I ² =	= 0%			
Test for overall effect:	Z=1.26 ((P = 0.2)	21)				Favours [LNU] Favours [ONU]
Total complication	ns LNU	1	ONU	J		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ariane 2012	19	150	61	495	32.0%	1.03 [0.59, 1.79]	
Blackmur 2015	10	13	9	13	2.7%	1.48 [0.26, 8.50]	
Hanske 2015	77	599	27	297	40.6%	1.48 [0.93, 2.34]	+=-
Hemal 2008	3	21	5	27	4.8%	0.73 [0.15, 3.49]	
Rouprêt 2007	3	20	4	26	3.8%	0.97 [0.19, 4.93]	
Stewart 2011	8	23	10	39	6.3%	1.55 [0.50, 4.74]	
Terakawa 2008	7	120	8	120	9.7%	0.87 [0.30, 2.47]	
Total (95% CI)		946		1017	100.0%	1.22 [0.91, 1.65]	•
Total events	127		124				
Heterogeneity: Chi ² =	2.12, df =	6 (P =	0.91); l ² =	= 0%			
Test for overall effect:	Z=1.32 ((P = 0.1	9)				Favours [LNU] Favours [ONU]
			Figure 3	3. Fore	st plot and	d meta-analysis of com	nplications.

3.5. Sensitivity analysis and publication bias

Sensitivity analysis was performed by removing one study at a time. The significance of the pooled comparison between the 2 groups was not influenced by removing any single study, indicating that the results of our meta-analysis were stable. Egger's test and Begg's test were used to assess the publication bias of the included studies. The results are shown in Table 4. Although Begg's test showed no evidence of publication bias for 5-year CSS, Egger's test showed potential evidence of publication bias (P=.044). However, the results were not influenced after adjustment for publication bias using the trimand-fill method.

4. Discussion

Since the first report comparing LNU to ONU were published in 1993,^[36] numerous trials have attempted to prove LNU as a feasible alternative of ONU for UTUC, but there is a lack of

comprehensive comparison. Our present meta-analysis provided high-level evidence to establish the role of LNU in the surgical treatment of UTUC. The results demonstrated that LNU was associated with longer operation time (P < .001), shorter hospital stay (P < .001), less blood loss (P = .006), and lower rate of transfusion (P < .001). The complication and survival parameters of LNU were comparable with ONU.

The process of LNU consists of nephrectomy and distal ureterectomy, with the same oncological principle as ONU. Laparoscopic access can be conducted via transperitoneal or retroperitoneal spaces. Transperitoneal access provides more working space and easier manipulation, while retroperitoneal approach avoids disruption of the intraperitoneal organs and risk of intraperitoneal contamination by malignant cells.^[37] The procedure of LNU has not yet been standardized, especially management of the distal ureter remains controversial. Various disposal methods have been described in the trials included in our meta-analysis, including open surgery,^[26,31] the Pluck technique,^[10,32] and the LigaSure Atlas system.^[27] Open surgery

5-year RFS	LNI	í	ONI	i i		Risk Ratio	Risk Ratio
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	M-H. Random, 95% Cl
Ariane 2012	78	150	233	459	8.1%	1.02 [0.86, 1.22]	+
Blackmur 2015	1	13	0	13	0.1%	3.00 [0.13, 67.51]	10
Capitanio 2009	234	270	746	979	11.7%	1.14 [1.07, 1.21]	•
Fairey 2012	147	446	173	403	8.2%	0.77 [0.65, 0.91]	-
Favaretto 2010	22	53	41	109	3.4%	1.10 [0.74, 1.65]	+
Fradet 2014	245	345	205	267	10.8%	0.92 [0.84, 1.02]	•
Hemal 2008	19	21	24	27	7.7%	1.02 [0.84, 1.23]	Ť
Kim 2016	67	100	161	272	8.4%	1.13 [0.96, 1.34]	
Kitamura 2014	19	34	44	65	4.2%	0.83 [0.59, 1.16]	
Liu 2017	32	52	104	213	5.9%	1.26 [0.98, 1.63]	
Metcalfe 2012	234	446	179	403	9.3%	1.18 [1.03, 1.36]	Ē
Terakawa 2008	58	120	54	120	5.6%	1.07 [0.82, 1.41]	J
Walton 2010	44	100	518	703	7.9%	0.85 [0.71, 1.03]	1
Xylinas 2013	/9	132	234	350	8.1%	0.90 [0.76, 1.05]	
Total (95% CI)		2252		4383	100.0%	1.01 [0.92 1.10]	•
Total events	1279	LLUL	2716	4505	100.07	101 [0.02, 1110]	
Heterogeneity Tau ² =	0 02 Ch	$i^2 = 45$	40 df = 1	3 (P < 1	0.00013-1	² = 71%	
Test for overall effect	Z = 0.13	(P = 0.9)	0)				0.02 0.1 1 10 50
5 year CSS			- S.				Favours (LNU) Favours (ONU)
J-year CSS	LNU	J	ONU	J		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Ariane 2012	136	150	358	459	10.3%	1.16 [1.08, 1.25]	
Blackmur 2015	8	13	9	13	0.8%	0.89 [0.51, 1.56]	
Capitanio 2009	232	270	715	979	10.8%	1.18 [1.11, 1.25]	
Fairey 2012	339	446	294	403	9.8%	1.04 [0.96, 1.13]	
Greco 2009	53	70	51	70	4.6%	1.04 [0.86, 1.26]	
Hemal 2008	20	21	25	27	6.5%	1.03 [0.89, 1.19]	
Kim 2016	76	100	223	271	7.4%	0.92 [0.82, 1.04]	
Kitamura 2014	25	34	56	65	3.8%	0.85 [0.68, 1.07]	
Metcalfe 2012	387	446	310	403	10.6%	1.13 [1.06, 1.20]	
Rouprêt 2007	18	20	16	26	2.0%	1.46 [1.04, 2.05]	
Simone 2009	32	40	36	40	4.9%	0.89 [0.74, 1.07]	
Stewart 2011	16	23	31	39	2.3%	0.88 [0.64, 1.20]	
Terakawa 2008	110	120	110	120	10.0%	1.00 [0.93, 1.08]	
vvaldert 2008	36	43	47	59	4.9%	1.05 [0.87, 1.26]	
Walton 2010	53	70	530	703	6.7%	1.00 [0.87, 1.15]	
Zou 2014	18	21	88	101	4.7%	0.98 [0.81, 1.19]	
Total (05% CI)		1007		3770	100.0%	1 0 4 10 00 1 101	•
Total evente	1650	1007	2000	5//0	100.078	1.04 [0.33, 1.10]	•
Hotorogeneity Tau?-	0.01.Ch	2 - 40	2055 70 df = 1	5 (P - 1	00045-1	2-63%	
Test for overall effect	7=1.54	P = 0.1	2)	50-0	0.0004),1	- 05 %	0.5 0.7 1 1.5 2
Testion overall ellect.	2-1.34	(r = 0.1	2)				Favours [LNU] Favours [ONU]
5-year OS	I NI		ONI	1		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% Cl	M-H. Bandom, 95% CI
Blackmur 2015	7	13	Q	13	2.0%	0.78 (0.42 1.45)	
Fairey 2012	303	446	270	403	19.9%	1 01 0 92 1 11	-
Favaretto 2010	38	53	73	109	10.7%	1.07 [0.86, 1.33]	_
Hemal 2008	18	21	23	27	9.6%	1.01 [0.80, 1.27]	
1 iu 2017	39	52	129	213	121%	1 24 [1 02 1 50]	_ _
Metcalfe 2012	365	446	265	403	20.8%	1.24 [1.15, 1.35]	
Stewart 2011	14	23	25	39	4.4%	0.95 [0.63, 1.42]	
Terakawa 2008	108	120	107	120	20.5%	1.01 [0.93, 1.10]	-+
Total (95% CI)		1174		1327	100.0%	1.08 [0.98, 1.18]	•
Total events	892		901				
Heterogeneity: Tau ² =	0.01; Ch	i ² = 19.3	22, df = 7	(P = 0.	008); l² =	64%	0.5 0.7 1 1.5 2
Test for overall effect:	Z=1.62	(P = 0.1)	1)				Favours [LNU] Favours [ONU]
2-year RFS	I MP		ONU			Rick Ratio	Rick Patio
Study or Subaroup	Evente	Total	Evente	Total	Weight	M.H. Fixed, 95% Cl	M.H. Fixed, 95% Cl
Koda 2007	57	70	19	27	12 20%	1 08 0 80 1 461	
Manabe 2007	44	58	136	166	32.3%	0.93 [0.79. 1.09]	
Miyazaki 2016	86	222	204	527	55.4%	1.00 [0.82, 1.22]	
Net (M) - Separate Anna -							
Total (95% CI)		359		720	100.0%	0.99 [0.87, 1.12]	T
Total events	187		358				
Heterogeneity: Chi ² =	U.98, df =	2 (P = (J.61); ² =	0%		0.2	0.5 1 2 5
Test for overall effect.	Z = 0.21 (P = 0.84	4)			0.2	Favours [experimental] Favours [control]
2-year CSS						Dict Date	Disk Date
0	1-1	LNU		ONU		Risk Ratio	Risk Ratio
Study of Subgroup	É	rents	TOTAL EV	ents	total We	eignit M-H, Hxed, 95% C	M-H, Fixed, 95% Cl
Favaretto 2010		43	53	94	109 1	0.7% 0.94 [0.81, 1.09	
Manape 2007		49	58	144	100 1	9.0% 0.97 [0.86, 1.10	
miyazaki 2016	000	169	222	385	527 51	5.2% 1.04 (0.95, 1.14	
i aweemonkongsap 2	008	21	31	21	29	1.170 0.94 [0.79, 1.11	1 [©]
Total (95% CI)			364		831 10	0.0% 1.01 [0 94 1 07	i 🔶
Total events		288	304	650	551 10		Ť
Heterogeneity Chi2 =	2.32 df=	3 (P = 1).51): P=	0%			
Test for overall effect	Z=0.17 (P=0.8	3)				0.7 0.85 1 1.2 1.5
2-vear OS							Favours [LNU] Favours [ONU]
2-year US		LNU		ONU		Risk Ratio	Risk Ratio
Study or Subgroup	E	vents	Total Ev	ents	Total We	eight M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Manabe 2007		49	58	139	166 2	1.7% 1.01 (0.89. 1.15	
Miyazaki 2016		161	222	366	527 6	5.5% 1.04 (0.95, 1.15	i - ¦≣
Rouprêt 2007		18	20	20	26	5.3% 1.17 (0.91, 1.51	· · · · · · · · · · · · · · · · · · ·
Taweemonkongsap 2	2008	27	31	24	29	7.5% 1.05 (0.85, 1.30	· · · · · · · · · · · · · · · · · · ·
		9212		1512	03350 81		,
Total (95% CI)			331		748 10	0.0% 1.04 [0.97, 1.12	1 +
Total events		255		549			
Heterogeneity: Chi ² =	1.03, df=	3 (P = 0	0.79); l² =	0%			07 085 1 12 15
Test for overall effect.	Z=1.14 (P = 0.25	5)				Favours [LNU] Favours [ONU]

Figure 4. Forest plot and meta-analysis of survival. CSS=cancer-specific survival, OS=overall survival, RFS=recurrence-free survival.

Table	4				
Egger's	test	and	Begg's	test	results

Egger e teet and E	-330. 0 1001 0								
Outcome of	Number of	P value of	P value of						
interest	included trials	Egger's test	Begg's test						
Operation time	13	.566	.903						
Hospital stay	11	.563	.938						
Estimated blood loss	9	.283	.677						
Complication	7	.405	.652						
5-year RFS	14	.253	.903						
5-year CSS	16	.044	.471						
5-year OS	8	.565	.621						

CSS = cancer-specific survival, OS = overall survival. Egger's test and Begg's test are not applicable when the included trials are < 5, RFS = recurrence-free survival.

remains most popular for bladder cuff excision. Nonetheless, no significant difference in oncological outcomes was reported among different techniques.^[38] Subgroup analysis could not be performed based on different procedures due to insufficient data.

As a mini-invasive procedure, LNU has been accepted worldwide as a promising option, with certain advantages over ONU in terms of less blood loss, less requirement of transfusion, shorter hospital stay and lower financial cost.^[39] But interestingly, in our meta-analysis, there was no significant difference in the occurrence of complications, including minor complications with Clavien grades 1 to 2 and major complications with Clavien grades 3 to 5. This is probably because enlarged incisions are necessary even in LNU for the removal of detached specimens as well as bladder cuff.

Previously, invasive or large tumors were contraindications for LNU.^[2] Given the improvement of techniques and surgeons' experience, the criteria of LNU have been dramatically expanded. In our meta-analysis, patients with high stages (T3/T4) and high grades (G3) also underwent LNU, resulting in similar oncological outcomes as ONU. Despite different techniques, the oncological principles of surgical treatment of UTUC are the same. However, the high risk of regional recurrence and port-site metastasis in LNU remains concerning. Kondo et al^[40] determinate that template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer, however, templated lymphadenectomy is difficult for laparoscopic approach.

Xylinas et al^[41] indicated that laparoscopic approach was an independent risk factor of intravesical recurrence, because high pressure might trigger tumor dissemination. Ariane et al^[10] reported a significant number of port-side seeding cases in the LNU group. In contrast, other studies suggested that surgical modalities did not influence the postoperative recurrence or survival.^[42–44]

Two meta-analyses have previously compared LNU and ONU, whereby LNU showed improvement in CSS and extravesical recurrence-free survival.^[5,45] Nevertheless, based on the trials published in the last 10 years, either the 5-year survival or the 2-year survival variables did not differ between LNU and ONU. Moreover, we also focused on the perioperative parameters such as operation time, hospital stay and blood loss.

Our meta-analysis had some inherent limitations. First, only studies published in English were pooled in our analysis. Hence, relevant studies published in other languages might have been missed. Second, although Begg's and Egger's tests were performed, the influence of bias in this study could not be completely excluded. Third, the pathological variables, the length of follow-up, the operation procedures and the surgeons' experience were not the same in the trials, and the influence of heterogeneity could not be evaluated. Last, only one of the 25 trials included in our meta-analysis was an RCT, which lowered the strength of this meta-analysis.

A meta-analysis of comparative trials published in the last 10 years was performed to evaluate the efficacy and safety of LNU in the treatment of UTUC. The results revealed that LNU was a feasible alternative to ONU with similar oncological outcomes. Further multicenter RCTs with large sample size and high quality are required, including detailed data of patients' clinical characteristics, standard surgery procedures and fixed assessment point after operations.

Acknowledgment

The authors would like to thank editor and anonymous referees for their valuable and informative comments.

Author contributions

Conceptualization: Feng Liu, Zhixin Wang.

- Data curation: Feng Liu, Wei Guo, Xueying Zhou, Youpeng Ding, Yanan Ma, Yi Hou, Xiangbo Kong.
- Formal analysis: Feng Liu, Wei Guo, Xueying Zhou, Youpeng Ding, Yanan Ma, Yi Hou, Xiangbo Kong, Zhixin Wang.
- Project administration: Zhixin Wang.

Writing - original draft: Feng Liu.

Writing – review & editing: Wei Guo, Xueying Zhou, Youpeng Ding, Yanan Ma, Yi Hou, Xiangbo Kong, Zhixin Wang.

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
- [2] Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868–79.
- [3] Clayman RV, Kavoussi LR, Figenshau RS, et al. Laparoscopic nephroureterectomy: initial clinical case report. J Laparoendosc Surg 1991;1:343–9.
- [4] Micali S, Celia A, Bove P, et al. Tumor seeding in urological laparoscopy: an international survey. J Urol 2004;171:2151–4.
- [5] Ni S, Tao W, Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012;61:1142–53.
- [6] GA Wells, B Shea, D O'Connell, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available at: http://wwwohrica/programs/clinical_epidemiol ogy/oxfordasp. 2011.
- [7] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
- [8] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
- [9] Duval S, Tweedie R, Nonparametric A. "Trim and Fill" method of accounting for publication bias in meta-analysis. J Am Stat Assoc 2000; 95:89–98.
- [10] Ariane MM, Colin P, Ouzzane A, et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012;19: 301–8.
- [11] Blackmur JP, Stewart GD, Egong EA, et al. Matched-pair analysis of open versus laparoscopic nephroureterectomy for upper urinary tract urothelial cell carcinoma. Urol Int 2015;94:156–62.
- [12] Capitanio U, Shariat SF, Isbarn H, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multiinstitutional analysis of 1249 cases. Eur Urol 2009;56:1–9.

- [13] Fairey AS, Kassouf W, Estey E, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU Int 2013;112:791–7.
- [14] Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol 2010;58:645–51.
- [15] Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol 2014;32:839–45.
- [16] Greco F, Wagner S, Hoda RM, et al. Laparoscopic vs open radical nephroureterectomy for upper urinary tract urothelial cancer: oncological outcomes and 5-year follow-up. BJU Int 2009;104:1274–8.
- [17] Hanske J, Sanchez A, Schmid M, et al. A comparison of 30-day perioperative outcomes in open versus minimally invasive nephroureterectomy for upper tract urothelial carcinoma: analysis of 896 patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. J Endourol 2015;29:1052–8.
- [18] Hemal AK, Kumar A, Gupta NP, et al. Retroperitoneal nephroureterectomy with excision of cuff of the bladder for upper urinary tract transitional cell carcinoma: comparison of laparoscopic and open surgery with long-term follow-up. World J Urol 2008;26:381–6.
- [19] Kim HS, Ku JH, Jeong CW, et al. Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma. World J Urol 2016;34:859–69.
- [20] Kitamura H, Maeda T, Tanaka T, et al. Comparison of laparoscopic, hand-assisted, and open surgical nephroureterectomy. JSLS 2014;18: 288–93.
- [21] Koda S, Mita K, Shigeta M, et al. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. Jpn J Clin Oncol 2007;37:296–301.
- [22] Liu JY, Dai YB, Zhou FJ, et al. Laparoscopic versus open nephroureterectomy to treat localized and/or locally advanced upper tract urothelial carcinoma: oncological outcomes from a multicenter study. BMC Surg 2017;17:8.
- [23] Manabe D, Saika T, Ebara S, et al. Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007;69:457–61.
- [24] Metcalfe M, Kassouf W, Rendon R, et al. Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Can Urol Assoc J 2012;6:455–62.
- [25] Miyazaki J, Nishiyama H, Fujimoto H, et al. Laparoscopic versus open nephroureterectomy in muscle-invasive upper tract urothelial carcinoma: subanalysis of the multi-institutional National Database of the Japanese Urological Association. J Endourol 2016;30:520–5.
- [26] Roupret M, Hupertan V, Sanderson KM, et al. Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: a single center experience. Urology 2007;69: 656–61.
- [27] Simone G, Papalia R, Guaglianone S, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol 2009;56:520–6.
- [28] Stewart GD, Humphries KJ, Cutress ML, et al. Long-term comparative outcomes of open versus laparoscopic nephroureterectomy for upper urinary tract urothelial-cell carcinoma after a median follow-up of 13 years*. J Endourol 2011;25:1329–35.

- [29] Taweemonkongsap T, Nualyong C, Amornvesukit T, et al. Outcomes of surgical treatment for upper urinary tract transitional cell carcinoma: comparison of retroperitoneoscopic and open nephroureterectomy. World J Surg Oncol 2008;6:3.
- [30] Terakawa T, Miyake H, Hara I, et al. Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. J Endourol 2008;22:1693–9.
- [31] Waldert M, Remzi M, Klingler HC, et al. The oncological results of laparoscopic nephroureterectomy for upper urinary tract transitional cell cancer are equal to those of open nephroureterectomy. BJU Int 2009; 103:66–70.
- [32] Walton TJ, Novara G, Matsumoto K, et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011;108:406–12.
- [33] Xylinas E, Colin P, Audenet F, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol 2013;31:61–8.
- [34] Yafi FA, Novara G, Shariat SF, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 2012;110:E7–13.
- [35] Zou L, Zhang L, Zhang H, et al. Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. World J Urol 2014;32:565–70.
- [36] Rassweiler JJ, Henkel TO, Potempa DM, et al. The technique of transperitoneal laparoscopic nephrectomy, adrenalectomy and nephroureterectomy. Eur Urol 1993;23:425–30.
- [37] Rai BP, Shelley M, Coles B, et al. Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int 2012;110:1426–35.
- [38] Li WM, Shen JT, Li CC, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010;57:963–9.
- [39] Meraney AM, Gill IS. Financial analysis of open versus laparoscopic radical nephrectomy and nephroureterectomy. J Urol 2002;167:1757–62.
- [40] Kondo T, Hara I, Takagi T, et al. Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. Int J Clin Oncol 2017;22:145–52.
- [41] Xylinas E, Kluth L, Passoni N, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decisionmaking tool. Eur Urol 2014;65:650–8.
- [42] Ishikawa S, Abe T, Shinohara N, et al. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. J Urol 2010;184:883–7.
- [43] Kobayashi Y, Saika T, Miyaji Y, et al. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol 2012;30:271–5.
- [44] Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015;67: 803–12.
- [45] Zhang S, Luo Y, Wang C, et al. Long-term oncologic outcomes of laparoscopic nephroureterectomy versus open nephroureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis. Peer J 2016;4:e2063.